CT Findings of Multifocal Hypervascular Hepatocellular Carcinoma With Intratumoral Pseudoaneurysm

- October 03, 2026

Edited by ScholarGen MediAI Editorial Team

When a Hypervascular Liver Mass Is More Than a Diagnosis

Executive Answer

Multifocal hypervascular hepatic tumors demonstrating arterial phase hyperenhancement, portal venous washout, extensive necrosis, and prominent intratumoral vascular structures strongly raise concern for hepatocellular carcinoma (HCC) in the appropriate clinical setting. In this case, the most clinically important imaging feature is an aneurysmal or pseudoaneurysmal vascular outpouching within the dominant exophytic hepatic tumor. This finding is important because it may indicate a vascular complication with potential hemorrhagic or rupture risk. The radiologist must therefore evaluate not only tumor diagnosis and extent, but also vascular anatomy, treatment implications, and potential complications.

Why This Case Matters

A large liver mass is not defined simply by its size.
For the radiologist, the more important questions are:
How does the tumor enhance?
What does its vascular architecture look like?
Is there necrosis or hemorrhage?
Is the tumor invading or displacing adjacent structures?
Could an abnormal intratumoral vessel represent a pseudoaneurysm?
And finally:
Could any of these findings change the patient's immediate clinical management?
This case illustrates why multiphasic CT interpretation of a hypervascular liver tumor should extend beyond simply recognizing HCC.
A woman in her mid-60s presented with weight loss and recently worsening abdominal pain. Contrast-enhanced CT demonstrated a dominant exophytic hepatic mass accompanied by multiple hepatic lesions. The dominant tumor contained extensive necrosis and prominent internal vascular structures. A focal aneurysmal or pseudoaneurysmal vascular outpouching was also identified.
The combination of multifocal hypervascular liver tumors, arterial phase hyperenhancement (APHE), washout, necrosis, and abnormal intratumoral vascularity creates a high-risk imaging pattern.
The critical lesson is:
The diagnosis may be HCC, but the vascular complication may be the finding that changes the urgency of the case.

Clinical Scenario

The patient was a woman in her mid-60s with weight loss and worsening abdominal pain.
The CT examination demonstrated:
A dominant exophytic hepatic mass
Multiple hepatic lesions
Marked arterial enhancement
Relative washout on later phases
Extensive internal necrosis
Prominent intratumoral vascular structures
An aneurysmal or pseudoaneurysmal vascular outpouching
Mass effect on adjacent abdominal structures
Medial displacement of the right kidney
Small-volume ascites
Mild peritoneal thickening
A right Spigelian hernia containing small bowel without definite obstruction
The clinical symptoms are also important.
Weight loss can accompany advanced malignancy, while worsening abdominal pain may have several potential explanations in a patient with a large hepatic tumor. In this case, the presence of an abnormal intratumoral vascular structure makes vascular complications particularly important to consider.

Dominant Exophytic Hepatic Mass

Figure 1. Coronal and sagittal contrast-enhanced CT.
A dominant exophytic hepatic mass demonstrates extensive internal necrotic areas and prominent intratumoral vascular channels.
ALT text:
`Coronal and sagittal contrast-enhanced CT showing a large exophytic hepatic mass with necrosis and prominent intratumoral vessels.`
The first major imaging question is:
Where does the mass originate?
An exophytic hepatic tumor can project beyond the normal hepatic contour and occupy a substantial portion of the abdominal cavity. When a large tumor extends away from the liver, its organ of origin may become less immediately obvious.
The relationship between the tumor and the liver should therefore be carefully assessed.
In this case, the dominant lesion is described as hepatic in origin and exophytic in growth pattern. The tumor extends into the abdominal cavity and produces substantial mass effect.
This matters for both diagnosis and treatment planning.
A large exophytic tumor may:
distort normal anatomy,
displace adjacent organs,
alter vascular relationships,
complicate surgical planning,
and potentially increase concern for rupture or hemorrhagic complications.
The important point is that tumor geometry is clinically meaningful.

Pathophysiology: Why Is HCC Hypervascular?

Hepatocellular carcinoma develops a vascular environment that differs from normal hepatic parenchyma.
Normal liver tissue receives dual blood supply from the portal vein and hepatic artery. During hepatocarcinogenesis, the vascular architecture of the tumor changes, with increasing arterialization and abnormal tumor angiogenesis.
This altered vascular supply contributes to:
Arterial phase hyperenhancement (APHE)
followed by:
Relative washout on portal venous or delayed imaging.
These temporal changes in enhancement are among the most important imaging features used when evaluating HCC.
LI-RADS provides a standardized framework for assessing liver observations in patients at risk for HCC, incorporating features such as nonrim APHE, nonperipheral washout, enhancing capsule, and threshold growth.
However, this case highlights an additional issue:
The morphology of the tumor vessels may be as important as the degree of enhancement.

Multifocal Hypervascular Liver Lesions

Multiple hypervascular liver lesions require a structured differential diagnosis.
Potential considerations include:
Multifocal HCC
Intrahepatic spread of HCC
Hypervascular metastases
Combined hepatocellular-cholangiocarcinoma
Vascular benign or malignant hepatic tumors
Other less common primary hepatic neoplasms
Multiplicity alone does not establish HCC.
However, when a dominant lesion demonstrates a highly characteristic HCC enhancement pattern and additional lesions show similar vascular behavior, multifocal HCC becomes an important consideration.
The clinical history and evaluation of other organs remain essential.

Intratumoral Pseudoaneurysmal Vascular Outpouching

Figure 2. CT angiography: sagittal portal venous phase and coronal arterial phase.
The dominant hepatic tumor contains an aneurysmal or pseudoaneurysmal vascular outpouching. The abnormal vascular structure is particularly conspicuous during the arterial phase.
ALT text:
`CT angiography showing an intratumoral aneurysmal or pseudoaneurysmal vascular outpouching within a hypervascular hepatic tumor.`
This is the most important imaging feature of the case.
A pseudoaneurysm is different from an ordinary intratumoral vessel.
A true aneurysm represents dilation of a vessel with preservation of the arterial wall architecture. A pseudoaneurysm develops after disruption of the vessel wall, allowing blood to extend into surrounding tissue while remaining contained.
Within a rapidly growing malignant tumor, abnormal angiogenesis, vascular remodeling, tissue necrosis, and structural vascular weakness may contribute to abnormal vascular morphology.
Therefore, a focal contrast-filled outpouching should not simply be dismissed as another tumor vessel.
The radiologist should ask:
Is the structure connected to an arterial branch?
Is it a true aneurysm or pseudoaneurysm?
Is there active extravasation?
Is there surrounding hemorrhage?
Is there evidence of tumor rupture?
Which artery supplies the tumor?
Could the finding affect interventional treatment?
This distinction can materially change the clinical pathway.

Why the Pseudoaneurysm Matters

The clinical importance of an intratumoral pseudoaneurysm lies in its potential relationship to hemorrhage and rupture.
This is particularly relevant in a patient with:
large tumor + exophytic growth + abdominal pain + abnormal intratumoral arterial structure.
The combination should prompt careful review of the arterial phase and consideration of vascular assessment when clinically appropriate.
CT angiography can help demonstrate:
feeding arteries,
abnormal arterial branches,
pseudoaneurysmal structures,
active bleeding,
vascular invasion,
and the vascular anatomy relevant to treatment.
If active tumor rupture or hemorrhage occurs, the clinical situation can become urgent.
Thus, the radiologist's report should not bury the vascular abnormality beneath a general statement such as:
“Findings are compatible with HCC.”
The vascular complication deserves explicit communication.

Figure 3 — Complex Imaging Pattern of Liver Cancer

Figure 3. Integrated CT findings of hypervascular liver malignancy.
The composite image demonstrates the major imaging components of the case, including hypervascularity, washout, extensive necrosis, exophytic growth, and multiple hepatic lesions.
ALT text:
`Composite CT illustration demonstrating hypervascularity, washout, necrosis, exophytic growth, and multifocal hepatic lesions.`
This figure is useful because no single feature establishes the complete clinical picture.
The diagnostic impression emerges from the combination of findings.

This integrated pattern strongly supports a malignant hypervascular hepatic process and, in the appropriate clinical context, raises strong concern for multifocal HCC.

Extensive Tumor Necrosis

Large malignant tumors may develop extensive necrosis when tumor growth exceeds the available blood supply.
Necrosis itself is not specific for HCC.
It can occur in many aggressive tumors.
Its diagnostic significance increases when it is interpreted together with the other imaging findings.
In this case, the extensive necrosis occurs within a large hypervascular tumor with abnormal intratumoral vessels and multifocal hepatic disease.
This provides information about tumor biology as well as morphology.
The radiologist should therefore distinguish:
tumor size
from
tumor architecture.
A large tumor is important.
But a large tumor with necrosis, abnormal vessels, and mass effect tells a much richer clinical story.

Radiologist's Reasoning: Seven Questions

Before finalizing the CT interpretation, the radiologist should systematically ask seven questions.

Question 1 — Is the mass truly hepatic in origin?

This is especially important for exophytic lesions.

Question 2 — Is there arterial phase hyperenhancement?

Determine whether the lesion demonstrates APHE and whether enhancement is homogeneous or heterogeneous.

Question 3 — Is there washout?

Compare the lesion with the surrounding liver on later phases.

Question 4 — Is there necrosis or hemorrhage?

Large malignant tumors may contain extensive necrosis.

Question 5 — Are there abnormal intratumoral vessels?

In this case, this is the critical question.
Look specifically for:
focal arterial outpouching,
pseudoaneurysm,
aneurysmal dilation,
active extravasation,
abnormal feeding vessels,
and vascular distortion.

Question 6 — Is there vascular invasion?

The portal and hepatic veins should be evaluated for tumor thrombus.

Question 7 — Is there extrahepatic disease?

Review:
lymph nodes,
peritoneum,
lungs,
bones,
adrenal glands,
and other abdominal organs.
This systematic approach reduces the risk of stopping the interpretation after recognizing the primary diagnosis.

Mass Effect and Right Kidney Displacement

Figure 4. Coronal contrast-enhanced arterial-phase CT.
The large hepatic tumor produces substantial mass effect, with medial displacement of the right kidney and alteration of the normal anatomic relationships of adjacent abdominal structures.
ALT text:
`Coronal arterial-phase CT showing medial displacement of the right kidney caused by a large hepatic tumor.`
Tumor size is not merely a number.
When a tumor becomes sufficiently large to displace adjacent organs, the spatial anatomy becomes important for treatment planning.
For surgical assessment, clinicians may need to consider:
residual liver volume,
vascular anatomy,
biliary anatomy,
tumor location,
adjacent organ involvement,
and the overall distribution of disease.
Therefore, CT serves not only as a diagnostic examination but also as an anatomic map for potential treatment planning.

Right Spigelian Hernia

Figure 5. Axial contrast-enhanced CT.
A right Spigelian hernia contains a contrast-filled small-bowel segment protruding through the hernial defect. No definite bowel obstruction is demonstrated.
ALT text:
`Axial contrast-enhanced CT showing a right Spigelian hernia containing a contrast-filled small-bowel loop.`
This finding is not the primary diagnosis.
But it is an important reminder:
The dominant diagnosis should never terminate the search.
Abdominal CT provides a wide field of view.
The radiologist must continue reviewing the bowel, mesentery, peritoneum, kidneys, pancreas, adrenal glands, pelvic organs, and other structures even after identifying a major malignancy.
A Spigelian hernia may require attention to:
bowel wall enhancement,
bowel wall thickness,
mesenteric vessels,
obstruction,
ischemia,
and strangulation.
In this case, definite obstruction was not identified.

Ascites and Peritoneal Thickening

Small-volume ascites and mild peritoneal thickening were also described.
These findings are nonspecific.
Ascites alone should not automatically be interpreted as peritoneal metastasis because it may occur in other clinical settings, including portal hypertension.
The radiologist should instead evaluate:
the amount and distribution of ascites,
nodular peritoneal thickening,
omental abnormalities,
lymphadenopathy,
vascular invasion,
and other extrahepatic disease.
The important lesson is:
Do not overcall a nonspecific finding.

Differential Diagnosis

Hypervascular Metastatic Neuroendocrine Tumor

Neuroendocrine tumors can produce hypervascular liver metastases.
When multiple hypervascular liver lesions are present, the possibility of a primary neuroendocrine tumor should be considered, particularly if there is a relevant history or an extrahepatic primary lesion.

Renal Cell Carcinoma Metastases

Renal cell carcinoma can also produce hypervascular liver metastases.
A history of renal malignancy would therefore be particularly important.

Combined Hepatocellular-Cholangiocarcinoma

Combined hepatocellular-cholangiocarcinoma can demonstrate overlapping features with HCC.
Atypical enhancement patterns or targetoid appearances should raise consideration of alternative primary hepatic malignancies.

Hemangioma and Other Vascular Lesions

Hemangioma is a common benign vascular liver lesion, but its characteristic enhancement pattern differs from typical HCC.

Hepatocellular Adenoma

Hepatocellular adenoma may be hypervascular in selected patients and can be associated with hemorrhagic complications.
Age, sex, medications, metabolic conditions, and imaging phenotype should therefore be integrated into the differential diagnosis.

When Is MRI Useful?

The presented case is centered on contrast-enhanced CT and CT angiography; MRI is not part of the available imaging material.
In clinical practice, liver MRI can provide additional lesion characterization through:
T1-weighted imaging
T2-weighted imaging
diffusion-weighted imaging
dynamic contrast enhancement
washout assessment
enhancing capsule
hepatobiliary-phase imaging
intralesional fat
hemorrhagic change
small satellite nodules
Gadoxetate-enhanced MRI may provide additional information during the hepatobiliary phase.
However, MRI is not automatically required for every hypervascular liver lesion.
The decision should depend on:
patient risk category,
CT diagnostic confidence,
lesion characteristics,
treatment planning,
and the clinical question that remains unanswered.

Diagnostic Risk: Why Could This Case Be Missed?

Several diagnostic vulnerabilities are possible.

Anchoring

Once HCC becomes the leading diagnosis, the radiologist may focus primarily on tumor staging and overlook an associated vascular complication.

Satisfaction of Search

Recognition of the dominant tumor may create an unconscious stopping point.

Arterial-Phase Oversight

A pseudoaneurysm may be much more conspicuous on arterial-phase imaging than on portal venous images.

Vascular Misclassification

An abnormal focal vascular outpouching may be mistaken for ordinary intratumoral vascularity.

Incomplete Field-of-View Review

The Spigelian hernia demonstrates how a secondary surgical finding can coexist with a major oncologic diagnosis.
The solution is not simply “look harder.”
A structured workflow helps:
Tumor → Enhancement → Necrosis → Vessels → Thrombus → Extrahepatic disease → Incidental findings

Clinical Significance and Treatment Planning

HCC treatment is not determined by tumor size alone.
The available case material emphasizes integration of:
tumor burden,
liver function,
vascular invasion,
extrahepatic spread,
performance status,
and treatment goals.
Potential treatment strategies include:

Surgical Resection

Selected patients may undergo resection when tumor distribution, liver function, anatomy, and adequate future liver remnant permit.

Liver Transplantation

Transplantation can be a curative option for selected patients, depending on tumor burden, vascular invasion, extrahepatic disease, and transplant criteria.

TACE

Transarterial chemoembolization is an important locoregional treatment option in appropriately selected patients.

TARE

Transarterial radioembolization may also be considered in selected clinical situations.

Systemic Therapy

Patients with disease unsuitable for resection or locoregional therapy may require systemic treatment, including contemporary immunotherapy-based strategies.
But this particular case contains an additional question:
What should be done about the abnormal intratumoral vascular structure?
When pseudoaneurysmal change is suspected, CT angiography or catheter angiography may be considered when clinically appropriate to define vascular anatomy and potential bleeding sources.
The oncologic problem and the vascular problem therefore need to be considered together.

Prognosis: Tumor Size Is Only One Variable

Prognostic assessment in HCC depends on multiple factors.
Relevant variables include:
tumor size,
tumor number,
vascular invasion,
extrahepatic spread,
liver function,
performance status,
tumor markers such as AFP,
treatment response,
and recurrence.
The available case information does not provide sufficient data to assign a definitive BCLC stage.
In particular, final staging would require additional information regarding vascular invasion, extrahepatic disease, liver function, and performance status.
Therefore, the correct approach is to describe what the CT demonstrates without overextending the available evidence.

AI Perspective: Where Could AI Help?

This case provides a realistic example of where clinical AI could potentially support radiology.
A liver-imaging AI system could potentially assist with:
liver lesion detection,
lesion segmentation,
lesion counting,
tumor volume estimation,
enhancement analysis,
multiphasic comparison,
vascular structure detection,
tumor thrombus assessment,
and worklist prioritization.
A more specialized vascular-analysis system could potentially flag an abnormal contrast-filled outpouching within a hypervascular tumor.
However, the case does not provide validated performance data for any AI system detecting pseudoaneurysm in HCC.
Therefore, no sensitivity, specificity, accuracy, or regulatory claims should be made.

AI as a Second Reader

The most realistic role for AI is not replacement of the radiologist.
It is attention support.
A conceptual workflow is:
AI detects or flags à Radiologist reviews à Radiologist verifies anatomy à Radiologist confirms vascular morphology à Radiologist integrates clinical context à Final interpretation

The radiologist remains responsible for determining whether a vascular structure actually represents a pseudoaneurysm and whether it has clinical significance.

AI Failure Modes

False Negative

An AI system may fail to detect a small or atypical pseudoaneurysm.

False Positive

A normal intratumoral vessel may be incorrectly flagged as a pseudoaneurysm.

Domain Shift

Performance may change with differences in scanners, contrast protocols, reconstruction techniques, patient populations, and acquisition timing.

Poor Image Quality

Motion or suboptimal arterial timing may reduce visibility of vascular abnormalities.

Anatomical Mislocalization

An AI system may identify enhancement but incorrectly assign its origin to the tumor.

Alert Fatigue

If too many findings are flagged, clinically important alerts may receive less attention.

Automation Bias

A radiologist may give excessive weight to an AI result.
The central principle is:
AI may redistribute attention, but it does not eliminate diagnostic responsibility.

Enterprise Imaging Workflow

If an AI capability for liver tumor and vascular analysis were implemented in an enterprise environment, a conceptual architecture could be:
DICOM à PACS à AI Orchestration à Liver/Vascular AI Model à Inference à PACS Visualization à Radiologist à RIS à EHR/EMR à Clinical Decision Support

The value of such a system would depend not only on algorithmic capability but also on workflow integration.
A clinically useful AI system must deliver the result:
at the appropriate time,
within the radiologist's existing workflow,
with sufficient visual evidence,
without excessive interruption,
and with a clear mechanism for human verification.

Healthcare-System Implications

A missed vascular complication can have consequences beyond the radiology report.
Potential downstream effects include:
Missed finding à Delayed recognition à Additional imaging or emergency evaluation à Treatment complexity à Additional resource utilization à Workflow burden

AI could potentially intervene at the detection or prioritization stage.
But AI should not automatically be assumed to reduce costs.
The economic value of an AI system depends on implementation cost, integration, maintenance, workflow redesign, adoption, false-positive burden, and whether earlier or more accurate recognition actually changes clinical management.

Practical Radiology Pearls

Pearl 1

A large exophytic hepatic mass requires deliberate confirmation of its hepatic origin.

Pearl 2

APHE and washout are central features in HCC imaging assessment.

Pearl 3

Multiple hypervascular liver lesions should not automatically be labeled HCC without appropriate clinical and imaging context.

Pearl 4

Extensive necrosis is nonspecific but becomes more informative when combined with hypervascularity, washout, and abnormal vascular architecture.

Pearl 5

A focal contrast-filled intratumoral outpouching deserves specific evaluation for aneurysm or pseudoaneurysm.

Pearl 6

Pseudoaneurysmal vascular change may indicate potential hemorrhagic or rupture risk.

Pearl 7

The portal and hepatic veins should be evaluated for tumor thrombus.

Pearl 8

Ascites alone does not establish peritoneal metastasis.

Pearl 9

A large tumor can significantly alter the anatomy of adjacent organs and affect treatment planning.

Pearl 10

A complete abdominal CT interpretation should continue after the primary diagnosis has been recognized.

Common Pitfalls

Pitfall 1 — “Hypervascular means HCC.”
Hypervascular metastases can mimic HCC.
Pitfall 2 — “The diagnosis is obvious, so the scan is complete.”
The vascular complication may be more clinically urgent than the diagnostic label itself.
Pitfall 3 — “All intratumoral vessels are tumor vessels.”
A focal aneurysmal or pseudoaneurysmal structure requires separate attention.
Pitfall 4 — “Ascites means peritoneal metastasis.”
Ascites is nonspecific.
Pitfall 5 — “The largest tumor determines stage.”
Staging requires integration of tumor burden, vascular invasion, extrahepatic disease, liver function, and performance status.
Pitfall 6 — “Negative AI means negative imaging.”
AI output is supportive and must be verified by the radiologist.

Frequently Asked Questions

What is the key CT pattern in this case?

The dominant pattern is multifocal hypervascular hepatic disease with arterial phase hyperenhancement, washout, extensive necrosis, and prominent intratumoral vascular structures.

What is the most important additional finding?

The most important additional finding is the focal aneurysmal or pseudoaneurysmal vascular outpouching within the dominant hepatic tumor.

Why is pseudoaneurysm important?

It may represent a vascular complication associated with potential hemorrhage or tumor rupture and may influence vascular assessment and treatment planning.

Does hypervascularity alone diagnose HCC?

No. Hypervascular metastases and other hepatic neoplasms may produce overlapping imaging findings.

When is MRI useful?

MRI can provide additional lesion characterization when CT findings remain uncertain or when additional information is clinically useful for characterization or treatment planning.

Is biopsy always required?

The need for biopsy depends on the patient's clinical risk group, imaging findings, diagnostic confidence, and management pathway. The available case does not provide sufficient information to establish whether biopsy was performed or required.

Can AI detect an intratumoral pseudoaneurysm?

AI could potentially support detection or prioritization, but this case does not provide validated performance data for such a system.

Can CT determine the final BCLC stage?

Not from the available information alone. Vascular invasion, extrahepatic spread, liver function, and performance status are also required.

Key Takeaways

This case demonstrates five major principles.
First, multifocal hypervascular liver tumors with APHE and washout should raise strong consideration of HCC in the appropriate clinical context.
Second, evaluate a large exophytic hepatic tumor not only for size but also for its spatial relationship with adjacent organs.
Third, extensive necrosis becomes more meaningful when integrated with the overall vascular and enhancement pattern.
Fourth, an intratumoral aneurysmal or pseudoaneurysmal outpouching is a clinically important finding that should be explicitly communicated and evaluated.
Fifth, modern radiology interpretation should connect the imaging diagnosis to diagnostic risk, treatment planning, workflow, and appropriate AI support.
The central lesson is therefore not simply:
“Is this HCC?”
It is:
“What does the imaging tell us about the tumor, its vascular risk, its extent, and the next clinical decision?”
That is the difference between recognizing a lesion and understanding a case.

MediAI Radiology Quiz

Question 1. Imaging Interpretation

A large hepatic mass demonstrates marked arterial phase hyperenhancement, relative washout on later phases, extensive necrosis, and multiple additional hepatic lesions. Which diagnosis is most strongly suggested in the appropriate clinical setting?
A. Hepatic hemangioma
B. Multifocal hepatocellular carcinoma
C. Simple hepatic cysts
D. Hepatic abscesses
E. Focal nodular hyperplasia
Correct Answer: B. Multifocal hepatocellular carcinoma
Explanation: The combination of arterial phase hyperenhancement, washout, extensive necrosis, and multifocal hepatic disease strongly raises concern for HCC in an appropriate at-risk clinical setting. Hypervascular metastases can demonstrate overlapping features, so clinical context and the complete imaging pattern remain essential.

Question 2. Vascular Complication

CTA demonstrates a focal contrast-filled aneurysmal or pseudoaneurysmal outpouching within the dominant hypervascular hepatic tumor. Why is this finding particularly important?
A. It confirms a benign vascular lesion.
B. It proves that the tumor is a hemangioma.
C. It may indicate a vascular complication with potential hemorrhagic or rupture risk.
D. It excludes malignant disease.
E. It indicates portal venous thrombosis.
Correct Answer: C. It may indicate a vascular complication with potential hemorrhagic or rupture risk.
Explanation: An intratumoral pseudoaneurysmal structure should not simply be interpreted as ordinary tumor vascularity. It may represent a clinically significant vascular complication and should prompt careful assessment of the feeding artery, active extravasation, surrounding hemorrhage, and potential implications for treatment planning.

Question 3. Differential Diagnosis

A patient has multiple hypervascular hepatic lesions. Which additional diagnosis should remain in the differential because it can produce hypervascular liver metastases?
A. Neuroendocrine tumor
B. Simple hepatic cyst
C. Acute cholecystitis
D. Uncomplicated diverticulosis
E. Hydronephrosis
Correct Answer: A. Neuroendocrine tumor
Explanation: Hypervascular hepatic metastases can occur with neuroendocrine tumors. Renal cell carcinoma and other hypervascular malignancies may also produce similar appearances. Therefore, multifocal hypervascular liver lesions should not automatically be labeled HCC without appropriate clinical and imaging context.

Question 4. Clinical Reasoning

In a patient with a very large exophytic hepatic tumor, which additional imaging feature should receive particular attention because it may alter immediate clinical management?
A. Mild fatty change of the liver
B. A small simple renal cyst
C. Intratumoral pseudoaneurysmal vascular change
D. Mild degenerative spine disease
E. A small hiatal hernia
Correct Answer: C. Intratumoral pseudoaneurysmal vascular change
Explanation: The dominant tumor itself establishes an important oncologic diagnosis, but an intratumoral pseudoaneurysm may introduce an additional vascular risk. Recognizing and communicating this finding may therefore be clinically important beyond routine tumor characterization and staging.

Question 5. AI-Assisted Imaging

An AI system flags a possible intratumoral pseudoaneurysm within a hypervascular liver tumor. What is the most appropriate next step for the radiologist?
A. Accept the AI result without further review.
B. Ignore the AI result because AI cannot detect vascular findings.
C. Verify the finding on the appropriate contrast phases and assess its vascular origin and clinical significance.
D. Automatically diagnose tumor rupture.
E. Automatically recommend surgery.
Correct Answer: C. Verify the finding on the appropriate contrast phases and assess its vascular origin and clinical significance.
Explanation: AI can potentially function as a detection or attention-support tool, but its output requires radiologist verification. The radiologist should determine whether the abnormal structure is truly aneurysmal or pseudoaneurysmal, identify its vascular origin, evaluate for active bleeding or rupture, and integrate the finding with the overall clinical context. The case does not provide validated performance data for any specific AI system.

Continue Learning

If you want to understand HCC imaging:
CT and MRI Imaging of Hepatocellular Carcinoma
If you want to understand the differential diagnosis:
Differential Diagnosis of Hypervascular Liver Lesions
If you want to understand radiology AI:
How AI Can Support Liver Tumor Detection on CT
If you want to understand interventional radiology:
CT Angiography and Transarterial Treatment of Hypervascular Liver Tumors

If you want to understand the broader topic:
AI in Abdominal and Oncologic Imaging

References

Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. DOI: 10.1097/HEP.0000000000000466.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. Journal of Hepatology. 2025;82(2):315–374. DOI: 10.1016/j.jhep.2024.08.028.
Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816–830. DOI: 10.1148/radiol.2018181494.
Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. Journal of Hepatology. 2026;84(3):631–654. DOI: 10.1016/j.jhep.2025.10.020.
Cho Y, Choi JW, Kwon H, et al. Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association. Korean Journal of Radiology. 2023;24(7):606–625. DOI: 10.3348/kjr.2023.0385.
Sandomenico F, Arpaia V, De Rosa F, et al. Spontaneously Ruptured Hepatocellular Carcinoma: Computed Tomography-Based Assessment. Diagnostics. 2023;13(6):1021. DOI: 10.3390/diagnostics13061021.
Yoshida H, Mamada Y, Taniai N, Uchida E. Spontaneous ruptured hepatocellular carcinoma. Hepatology Research. 2016;46(1):13–21. DOI: 10.1111/hepr.12498.
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021. DOI: 10.1038/s41572-020-00240-3.
Medical Disclaimer: This article is intended for educational and professional medical imaging discussion. It does not replace individualized diagnosis or treatment by qualified clinicians.

Comments